Pharmaceutical industry – Page 19
-
ArticleSmall particles making a big splash in clinical development
Nanoform is investigating how to tackle clinical attrition rates through nanonisation of APIs
-
ArticleInvestigating multi-dimensional problems in drug substance development
Finding solutions to the biggest challenges faced during drug substance development relies on properly integrating analytical and production expertise
-
NewsEU sets goal of tackling pharmaceutical pollution in the environment
Commission identifies six areas to take action on
-
BusinessSmartwound dressings spot infection early
Bacterial toxins burst dye-filled vesicles to give a visual warning
-
NewsUniversity sues professor for taking graduate’s research that he stands to make millions from
University of Missouri–Kansas City pharmacy researcher accused of stealing inventions related to a novel eye drug delivery formulation, sold it for $1.5m plus royalties
-
OpinionWe’re going to need a bigger flask
Scaling up reactions is easy to get wrong in a variety of ways
-
OpinionDivergent reality
If the UK leaves the EU without a deal, the two will inevitably drift further apart
-
BusinessWhat might Brexit mean for industry?
Questions hang over regulation, trade, talent and investment
-
-
OpinionIn search of ultimate selectivity
A catalyst that reacts only with aryl iodides, spurning bromides and chlorides
-
NewsBig costs, no benefits to UK’s replacement for EU chemical regulation
Industry warns small volume chemicals could no longer be sold in the UK
-
BusinessUK government sets out antimicrobial resistance plan
Aims to cut antibiotic use and explore financial incentives for pharmaceutical companies
-
BusinessBattling the US opioid epidemic
Adapt pharma’s naloxone nasal spray makes treating overdoses easier
-
ResearchPatent-busting AI tool navigates around protected drug pathways
Organic retrosynthesis software can identify key bonds involved in patented reactions to find alternative pathways
-
OpinionWhat are the rate-limiting steps in drug discovery?
Getting more drugs to market is not just a chemistry problem
-
BusinessPfizer to close two manufacturing plants in India
Closures will lead to the loss of 1700 jobs – almost 6% of the pharma giant’s manufacturing workforce
-
BusinessChinese plant closures disrupt supply chains
Environmental clampdown knocks out major suppliers of some ingredients
-
BusinessBristol-Myers Squibb to buy Celgene for $74 billion
Deal boosts BMS’s cancer and immunology pipeline with 5 drugs in late stage clinical trials
-
ArticleStrength through diversity
Why people should be at the heart of a forward-thinking contract research organisation
-
BusinessGSK and Pfizer joint venture creates new consumer healthcare giant
Enlarged GSK consumer health will have largest market share of any firm and be a leader in key countries